Although HER2-positive tumors harbored a higher TMB than HER2-low and HER2-zero tumors in HR+ breast cancer in the TCGA database, no difference in TMB among different subgroups was observed in our NGS database (Additional file 9: Fig. S3D). This evidence concerns the gene ERBB2 and breast carcinoma.